3 terminated, 2 active not recruiting, 2 withdrawn, 1 completed. 10 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Terminated 3, Active not recruiting 2, Withdrawn 2, Completed 1, Recruiting 1, Unknown 1 |
| Phase 2 | 4 | Recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
Follow pelcitoclax: new trials by email Literature Review of pelcitoclax trials Research Report on pelcitoclax
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML Azacitidine, APG1252 - AML | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 52 | 2026-05-22 | 2026-10-05 |
| A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia Fludarabine, Cytarabine, G-CSF - Phase I, FLAG Chemotherapy | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2026-04-27 | 2026-05-07 | |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma APG-1252, Chidamide - NHL, Adult | Phase 1 / Phase 2 | Unknown | Ascentage Pharma Group Inc. | 51 | 2022-06-14 | 2024-01-23 |
| A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors Pelcitoclax - Neuroendocrine Tumors | Phase 1 | Terminated | Ascentage Pharma Group Inc. | 2 | 2022-01-06 | 2025-04-17 |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy APG-1252, Ruxolitinib - Myelofibrosis | Phase 1 / Phase 2 | Withdrawn | Ascentage Pharma Group Inc. | 2020-12-15 | 2022-07-12 | |
| Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer APG-1252, Paclitaxel - Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Ascentage Pharma Group Inc. | 28 | 2020-08-20 | 2022-07-12 |
| A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients APG-1252, Osimertinib Mesylate Tablets - EGFR Positive Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Ascentage Pharma Group Inc. | 80 | 2019-07-04 | 2025-10-01 |
| APG-1252 in Patients With SCLC or Advanced Solid Tumors APG-1252 - Small Cell Lung Cancer and Other Solid Tumors | Phase 1 | Terminated | Ascentage Pharma Group Inc. | 24 | 2017-12-01 | 2021-08-27 |
| A Study of APG-1252 in Patients With SCLC or Other Solid Tumors APG-1252 - Small Cell Lung Cancer, Solid Tumor | Phase 1 | Completed | Ascentage Pharma Group Inc. | 50 | 2017-02-12 | 2022-07-12 |
Small Cell Lung Carcinoma (3) · Carcinosarcoma (1) · Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Neuroendocrine Tumors (1) · Polycythemia Vera (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Primary Myelofibrosis (1) · Recurrence (1) · Thrombocytosis (1)
Ascentage Pharma Group Inc. (7) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (1)
United States (5) · China (4) · Australia (1)
Yifan Zhai, MD, PhD (4) · Jie Chen, M.D., PhD. (1) · Joyce F Liu (1) · Li Zhang, Professor (1) · Minhu Chen, M.D., PhD. (1) · Nicholas J Short, MD (1) · Tapan Kadia, MD (1) · Xianjun Yu (1) · Yifan Zhai, M.D., Ph.D. (1)
UM1CA186709 (1)